.png)
.png)
NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and weight lowering than does escalating dulaglutide treatment. “Often, when we are with a patient who is not meeting treatment goals...
Copyright © 2024 buzzstream. All Rights Reserved
Copyright © 2024 BuzzStream. All Rights Reserved.
All content on this website, including but not limited to text, images, graphics, logos, articles, and other materials, is the property of BuzzStream and is protected by international copyright laws. No part of this content may be reproduced, distributed, transmitted, displayed, published, or broadcast without BuzzStream's prior written permission. Unauthorized use of the content is strictly prohibited and may result in legal action.
For inquiries regarding the use or licensing of content, please contact us at 1-832-482-2215.
Feel free to customize it further if needed!
